Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Ten analysts rate Black Diamond Therapeutics as a "Moderate Buy" (1 sell, 2 hold, 6 buy, 1 strong buy) with an average 12‑month price target of $10 and recent upgrades including Wedbush raising its target to $14 and Jefferies assigning a "strong‑buy".
• Institutional ownership: Large investors own roughly 95.47% of the stock, with several new small positions recently disclosed.
• Stock and business snapshot: Shares trade near $2.82 (market cap ~$161.6M, PE 7.62, 12‑month range $1.49–$4.94); the company beat quarterly EPS (-$0.14 vs. -$0.18) and is advancing lead candidate BDTX‑189, an allosteric inhibitor targeting mutant HER2.

Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a "buy" rating on shares of Black Diamond Therapeutics in a report on Wednesday, April 29th. Wedbush upped their price target on shares of Black Diamond Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a report on Tuesday, March 17th. Piper Sandler reduced their price target on shares of Black Diamond Therapeutics from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, January 16th. Jefferies Financial Group upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a report on Thursday, April 23rd. Finally, BTIG Research upped their price target on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a report on Wednesday, April 29th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Cerity Partners LLC acquired a new position in Black Diamond Therapeutics during the second quarter worth $26,000. Virtu Financial LLC acquired a new position in Black Diamond Therapeutics during the third quarter worth $39,000. Hudson Bay Capital Management LP acquired a new position in Black Diamond Therapeutics during the second quarter worth $26,000. nVerses Capital LLC acquired a new position in Black Diamond Therapeutics during the fourth quarter worth $26,000. Finally, Stokes Family Office LLC acquired a new position in Black Diamond Therapeutics during the fourth quarter worth $27,000. Institutional investors and hedge funds own 95.47% of the company's stock.

Black Diamond Therapeutics Stock Down 1.7%

Black Diamond Therapeutics stock opened at $2.82 on Thursday. The stock has a market capitalization of $161.59 million, a PE ratio of 7.62 and a beta of 3.34. Black Diamond Therapeutics has a twelve month low of $1.49 and a twelve month high of $4.94. The company has a 50 day moving average of $2.48 and a 200-day moving average of $2.85.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. Equities analysts anticipate that Black Diamond Therapeutics will post -0.6 EPS for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company's development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.